Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | August 15, 2026 | August 18, 2026 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,499 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 722 · Balance 12,762 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-08-17 · Sale · Disposed 263 · Balance 12,499 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 783 |
Reported balance
After 2026-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-15 · Exercise / conversion · Disposed 390 · Balance 783 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,993 |
Reported balance
After 2026-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-15 · Exercise / conversion · Disposed 332 · Balance 1,993 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:27 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 263 | $4.55 | $1,196.65 |
DisclosureSEC source: 0001193125-26-355722 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,499 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:27 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 332 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355722 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,993 Underlying: Common Stock · 332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:27 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355722 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 783 Underlying: Common Stock · 390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:27 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-355722 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001193125-26-300916 · ownership.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2036-07-07 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 259 | $7.53 | $1,950.27 |
DisclosureSEC source: 0001193125-26-230733 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,040 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-230733 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,325 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-230733 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,173 Underlying: Common Stock · 391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-230733 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057156 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,656 Underlying: Common Stock · 333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057156 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,564 Underlying: Common Stock · 391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 259 | $8.47 | $2,193.73 |
DisclosureSEC source: 0001193125-26-057156 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,577 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057156 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286235 · ownership.xml · derivative · entry 5 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286235 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,954 Underlying: Common Stock · 390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 217 | $17.30 | $3,754.10 |
DisclosureSEC source: 0001193125-25-286235 · ownership.xml · nonDerivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,113 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 331 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286235 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 390 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286235 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 217 | $16.65 | $3,613.05 |
DisclosureSEC source: 0000950170-25-110096 · ownership.xml · nonDerivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,609 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-110096 · ownership.xml · derivative · entry 5 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,320 Underlying: Common Stock · 333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-110096 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,344 Underlying: Common Stock · 391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-110096 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-110096 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 220 | $7.28 | $1,601.60 |
DisclosureSEC source: 0000950170-25-074327 · ownership.xml · nonDerivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,102 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 331 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074327 · ownership.xml · derivative · entry 5 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,653 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074327 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,735 Underlying: Common Stock · 390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 331 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074327 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 390 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074327 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 01:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 12,726 | $0.81 | $10,314.42 |
DisclosureSEC source: 0000950170-25-023575 · ownership.xml · nonDerivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,039 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8354, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 26,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023575 · ownership.xml · derivative · entry 5 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,687 Underlying: Common Stock · 26,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023575 · ownership.xml · derivative · entry 4 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 26,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023575 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:08 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 7,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023575 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 1,950,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-017912 · ownership.xml · derivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950,000 Underlying: Common Stock · 1,950,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 2,505 | $0.54 | $1,354.95 |
DisclosureSEC source: 0000950170-24-128609 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,389 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $ 0.5638, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128609 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,313 Underlying: Common Stock · 7,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 7,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128609 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 22:24 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 8,748 | $0.69 | $6,036.99 |
DisclosureSEC source: 0000950170-24-118409 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,082 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 4, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F4 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.69605, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:24 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 27,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118409 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:24 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 27,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118409 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 21:38 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 2,518 | $0.84 | $2,115.12 |
DisclosureSEC source: 0000950170-24-098712 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,993 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.880001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:38 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098712 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,125 Underlying: Common Stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:38 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 7,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-098712 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062059 · ownership.xml · derivative · entry 3 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,938 Underlying: Common Stock · 7,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 2,435 | $0.94 | $2,288.90 |
DisclosureSEC source: 0000950170-24-062059 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,698 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.950451, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 7,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-062059 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 16, 2024 Filed Feb 17, 2024 02:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 11,549 | $1.08 | $12,472.92 |
DisclosureSEC source: 0000950170-24-016710 · ownership.xml · nonDerivative · entry 2 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,321 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.1101, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016710 · ownership.xml · derivative · entry 6 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016710 · ownership.xml · nonDerivative · entry 1 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 106,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016710 · ownership.xml · derivative · entry 5 Shaff Eric D. · CIK 0001643734 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,250 Underlying: Common Stock · 106,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.